Ozempic & Wegovy: Potential Game Changers in Slowing Biological Aging
In a groundbreaking discovery that could revolutionize the use of popular weight-loss medications, researchers have found that semaglutide — the active ingredient in Ozempic and Wegovy — may do much more than just help in weight loss. A recent randomized, placebo-controlled clinical trial has provided the first clinical evidence in humans that a GLP-1 receptor agonist drug could potentially slow down the process of biological aging.
The study, spearheaded by UC San Diego’s School of Medicine and published in Nature Communications, involved 108 adults living with HIV-associated lipohypertrophy — a condition known to accelerate cellular aging. Over a span of 32 weeks, participants who received weekly semaglutide injections demonstrated a significantly slower progression of multiple epigenetic markers associated with aging, compared to those who were given a placebo. Remarkably, the rate of biological aging slowed by approximately 9%, as gauged by the DunedinPACE epigenetic clock — a tool that estimates biological age by analyzing DNA methylation patterns.
The benefits were observed across a wide range of organ systems, including the heart, brain, kidneys, liver, and metabolic health. Some participants also exhibited longer telomeres, indicating improved cellular resilience. The researchers propose that the mechanisms — including reduced inflammation and lower visceral fat — could extend well beyond HIV patients to the general population. However, they caution that semaglutide should not yet be labeled as an “anti-aging drug,” and that larger studies are necessary before making definitive conclusions.
📰 Source: TheDiggerNews – Ozempic and Wegovy May Slow Biological Ageing (July 15, 2026)